Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Anticoagulant Therapy in Patients with Severe Factor XI Deficiency

Mar Gutierrez Alvarino, Maria Isabel Rivas Pollmar, Nora Butta, Eduardo Garcia Perez, Victor Jimenez Yuste, Monica Martin Salces, Jose martin De Bustamante, maria Jesus Blanco Bañares, Mikel fernandez Artazkoz, Matias gabriel Facal, Patricia Gonzalez Marugan, Maria Asunción Hernandez Arriaza, María Teresa Álvarez Román

Blood (2024) 144 (Supplement 1): 5563.

https://doi.org/10.1182/blood-2024-204709

Published: 2024

Journal Articles

Monitoring the Hemostatic Effects of Inhibitory Alloantibodies in Von Willebrand Disease Using Global Coagulation Assays

Elena G Arias-Salgado, Nora Butta, Paula Acuña, Elena Monzón Manzano, Monica Martin Salces, Maria Isabel Rivas Pollmar, Rick Kapur, Víctor Jiménez-Yuste, María Teresa Alvarez-Román

Blood (2024) 144 (Supplement 1): 5470.

https://doi.org/10.1182/blood-2024-210405

Published: 2024

Journal Articles

Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Paula Acuña, Elena Monzón Manzano, María Teresa Alvarez-Román, Elena G Arias-Salgado, Eduardo Garcia Perez, Monica Martin Salces, Maria Isabel Rivas Pollmar, Rick Kapur, Victor Jimenez Yuste, Nora Butta

Blood (2024) 144 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2024-200067

Published: 2024

Journal Articles

B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing

Elena Monzón Manzano, María Teresa Alvarez-Román, Lucía del Pino, Paula Acuña, Rick Kapur, Leendert Porcelijn, Monica Martin Salces, Elena G Arias-Salgado, Maria Isabel Rivas Pollmar, Ana Mendoza, Eduardo López Granados, Victor Jimenez Yuste, Nora Butta

Blood (2024) 144 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2024-202993

Published: 2024

Journal Articles

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Tyler W. Buckner, Craig Kessler, Giancarlo Castaman, Cédric Hermans, Victor Jimenez-Yuste, Johnny Mahlangu, Wolfgang A. Miesbach, Johannes Oldenburg, Michael Recht, Leonard A. Valentino, Allison P Wheeler, Steven W. Pipe

Blood (2024) 144 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2024-194935

Published: 2024

Journal Articles

Physical and Psychological Burden on People with Hemophilia: Global Real-World Data

Giancarlo Castaman, Cléa Percier, Naveen Shridhar, Neil Reynolds, Olivera Rajkovic-Hooley, Thom Dewar, Víctor Jiménez-Yuste

Blood (2024) 144 (Supplement 1): 2318.

https://doi.org/10.1182/blood-2024-200033

Published: 2024

Journal Articles

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Tadashi Matsushita, Pratima Chowdary, Atanas Mitkov Banchev, Kaan Kavakli, Johanna A. Kremer Hovinga, Jerzy Windyga, Víctor Jiménez-Yuste, Julien Bovet, Llenalia María García Fernández, Guy Young

Blood (2024) 144 (Supplement 1): 718.

https://doi.org/10.1182/blood-2024-198617

Published: 2024

Journal Articles

Burden of Treatment on People with Hemophilia: Global Real-World Data

Víctor Jiménez-Yuste, Cléa Percier, Naveen Shridhar, Neil Reynolds, Olivera Rajkovic-Hooley, Thom Dewar, Giancarlo Castaman

Blood (2024) 144 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2024-200008

Published: 2024

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Víctor Jiménez-Yuste, Eunice Tzeng, Elise Lim, Giuliana Ventriglia, Amy D. Shapiro, Johannes Oldenburg, Johnny Mahlangu

Blood (2023) 142 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2023-173016

Published: 2023

Journal Articles

Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders

Nora Butta, Elena Monzón Manzano, Paula Acuña, Elena G Arias-Salgado, Maria Isabel Rivas Pollmar, Monica Martin Salces, Ana Mendoza-Martínez, Víctor Jiménez-Yuste, Waleed Ghanima, Maria Teresa Álvarez-Roman

Blood (2023) 142 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2023-188452

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Monitoring of Hemostatic Status and Treatment Response in Von Willebrand Disease Using a Microchip Flow Chamber Assay

Elena G Arias-Salgado, Paula Acuña, Elena Monzón Manzano, Monica Martin Salces, Maria Isabel Rivas Pollmar, Pilar Lopez Gotor, Nora Butta, Cedric R. Hermans, Víctor Jiménez-Yuste, Maria Teresa Álvarez-Roman

Blood (2023) 142 (Supplement 1): 5396.

https://doi.org/10.1182/blood-2023-187360

Published: 2023

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Víctor Jiménez-Yuste, Elise Lim, Ketna Mistry, Giuliana Ventriglia, Amy D. Shapiro

Blood (2023) 142 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2023-173081

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins

Blood (2023) 142 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2023-173015

Published: 2023

Journal Articles

Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Elena Monzón Manzano, Maria Teresa Álvarez-Roman, Paula Acuña, Elena G Arias-Salgado, Raquel Ramírez Martín, Maria Cristina Pascual Izquierdo, Maria Isabel Rivas Pollmar, Monica Martin Salces, Waleed Ghanima, Víctor Jiménez-Yuste, Nora Butta

Blood (2023) 142 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2023-185706

Published: 2023

Journal Articles

Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia

Mercedes Gasior Kabat, Elena Monzón Manzano, Paula Acuña, María Teresa Alvarez Román, Elena G Arias-Salgado, María Isabel Rivas Pollmar, Matias Facal Giuliani, Patricia Gonzalez Marugan, Sara García Barcenilla, Fernando Gomez Aguado, Concepción Ramos Castro, Cédric Hermans, Víctor Jiménez Yuste, Nora V. Butta

Blood (2022) 140 (Supplement 1): 12266–12267.

https://doi.org/10.1182/blood-2022-167776

Published: 2022

Journal Articles

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Joaquin Martinez Lopez, Javier De La Cruz, Rodrigo Gil-Manso, Celina Benavente Cuesta, Lauren Benito, jose Angel Hernandez, Maria Regina Herraez, Pilar Herrera Puente, Mi Kwon, Keina Quiroz, Andres Arroyo, Adrian Alegre, María Pilar Llamas Sillero, Javier López Jiménez, Pedro Sanchez-Godoy, Rafael F. Duarte, Jose L. Diez Martin, Víctor Jiménez-Yuste, Julio Garcia-Suarez

Blood (2022) 140 (Supplement 1): 7924–7925.

https://doi.org/10.1182/blood-2022-169545

Published: 2022

NARROW

Anticoagulant Therapy in Patients with Severe Factor XI Deficiency

Monitoring the Hemostatic Effects of Inhibitory Alloantibodies in Von Willebrand Disease Using Global Coagulation Assays

Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Physical and Psychological Burden on People with Hemophilia: Global Real-World Data

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Burden of Treatment on People with Hemophilia: Global Real-World Data

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Monitoring of Hemostatic Status and Treatment Response in Von Willebrand Disease Using a Microchip Flow Chamber Assay

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only